POTASSIUM-MAGNESIUM CITRATE AS A SURROGATE OF THE DASH DIET IN MANAGING HYPERTENSION
    2.
    发明申请
    POTASSIUM-MAGNESIUM CITRATE AS A SURROGATE OF THE DASH DIET IN MANAGING HYPERTENSION 审中-公开
    钾钛矿作为管理高血压的食物之一

    公开(公告)号:US20080193525A1

    公开(公告)日:2008-08-14

    申请号:US11673497

    申请日:2007-02-09

    申请人: Charles Y.C. Pak

    发明人: Charles Y.C. Pak

    IPC分类号: A61K33/14 A61K9/14

    摘要: The present invention includes compositions and methods for using a single pharmaceutical preparation of KMgCit is a convenient surrogate or to support the DASH diet in lowering blood pressure among patients with essential hypertension. Support is provided by potassium, magnesium and alkali, which overcome the underlying physiological-biochemical disturbances of essential hypertension, such as salt sensitivity, insulin resistance, low urinary pH, low serum magnesium and renal leak of calcium. Positive effects of KMgCitrate disclosed in normal subjects and patients with stones, provides assurance that KMgCitrate should ameliorate the above physiological-biochemical disturbances and associated disorders in patients with essential hypertension.

    摘要翻译: 本发明包括用于使用KMgCit的单一药物制剂的组合物和方法是方便的替代物,或支持DASH饮食以降低原发性高血压患者的血压。 支持由钾,镁和碱提供,克服了原始高血压的潜在生理生化障碍,如盐敏感性,胰岛素抵抗,低尿酸度,低血清镁和肾脏的钙渗漏。 正常人和石块患者揭示的KMg柠檬酸盐的正面作用,保证了维生素E对改善原发性高血压患者的生理生化干扰和相关疾病的保护作用。